Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q16585
UPID:
SGCB_HUMAN
Alternative names:
43 kDa dystrophin-associated glycoprotein; A3b
Alternative UPACC:
Q16585; B7Z635; O00661
Background:
Beta-sarcoglycan, also known as the 43 kDa dystrophin-associated glycoprotein or A3b, plays a crucial role in muscle function. It is a component of the sarcoglycan complex, which is part of the larger dystrophin-glycoprotein complex, linking the F-actin cytoskeleton to the extracellular matrix. This connection is vital for the integrity of muscle tissue.
Therapeutic significance:
Beta-sarcoglycan is implicated in Muscular dystrophy, limb-girdle, autosomal recessive 4, a condition characterized by muscle wasting and a variable progression rate. Understanding the role of Beta-sarcoglycan could open doors to potential therapeutic strategies for this degenerative myopathy.